MEVITEM—a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.